Gilead Falls as CVS Hasn’t Yet Added PrEP HIV Shot to Drug Plans

Gilead Sciences Inc.’s shares fell after CVS Health Corp said it hasn’t yet added its new HIV prevention shot to its commercial drug plans.

“As is typical with new-to-market products, we undergo a careful review of clinical, financial, and regulatory considerations,” CVS spokesperson David Whitrap said in a statement. At this time, Gilead’s drug hasn’t been added to CVS Caremark’s commercial drug plans or Affordable Care Act plans, Whitrap said.

Gilead’s shares fell as much as 3.5% in early trading in New York Thursday.

The decision, which was first reported by Reuters, potentially throws a wrench in Gilead’s plans ...